UFL Health and Baptist
Welcome,         Profile    Billing    Logout  
 1 Trial 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hudak, Mark L
NCT03978000 / 2018-000754-22: IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study

Active, not recruiting
3
2158
Europe, US, RoW
IBP-9414, Placebo
Infant Bacterial Therapeutics
Necrotizing Enterocolitis
06/24
07/24
SIL02, NCT03142568: Safety of Sildenafil in Premature Infants

Recruiting
2
120
Canada, US
Sildenafil, Revatio, Placebo, sugar water
University of North Carolina, Chapel Hill, Duke University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), The Emmes Company, LLC
Bronchopulmonary Dysplasia
02/25
04/25
SILDI-SAFE, NCT04447989: Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia

Active, not recruiting
2
120
US
Sildenafil, Revatio, Placebo, Dextrose 5%
Christoph Hornik, University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI)
Bronchopulmonary Dysplasia of Newborn
12/24
01/25

Download Options